PHQ-9 Scores Rose Alongside Physical Symptom Burden and Chronic Disease
A higher score on the Patient Health Questionnaire-9 tracked with a broader burden of illness in the Baseline Health Study, extending well beyond mood symptoms alone. In this cross-sectional analysis of 2,365 adults drawn to represent major demographic groups in the United States, participants with higher PHQ-9 scores were more likely to be women, younger, and physiologically less well than those with lower scores. Resting heart rate, body mass index, waist circumference, and several chronic conditions all shifted in parallel with worsening depressive symptom scores.
The clinical message is straightforward. Even when PHQ-9 scores do not cross the threshold for a major depressive disorder diagnosis, they may still flag a patient with accumulating medical and functional strain.
Deep Phenotyping Exposed a Broader Medical Pattern
The Baseline Health Study used deep phenotyping, with demographic, clinical, laboratory, functional, and imaging data collected at intake. That design matters because depressive symptoms rarely exist in isolation in real-world practice. They often travel with pain, autonomic symptoms, sleep disruption, gastrointestinal disease, reduced exercise tolerance, and a greater load of chronic illness. Here, the PHQ-9 functioned less like a narrow mental health screen and more like a window onto systemic health.
Several baseline characteristics moved in the same direction as PHQ-9 severity. Higher scores were associated with female sex, younger age, higher resting heart rates, larger body mass index, and greater waist circumference. Chronic disease also clustered more often among participants with higher scores, including gastro-oesophageal reflux disease and asthma. The pattern is biologically plausible: inflammatory signaling, symptom amplification, disrupted sleep, and reduced activity can reinforce one another across mood and somatic disease.
Somatic Symptoms and Daily Function Mapped Closely to PHQ-9 Severity
The strongest signal was not confined to diagnoses. Increasing PHQ-9 scores also tracked with a higher frequency of active symptoms and functional complaints, including migraines, leg cramps, mood change, and lack of energy. Those are not trivial add-ons to a depression screen; they are the everyday features that change how patients move through a clinic visit, how they tolerate treatment, and how much disease burden they can carry before decompensating.
After adjustment for demographic, socioeconomic, behavioural, and medical characteristics, several symptoms remained associated with higher PHQ-9 scores. Memory change, tension, shortness of breath, backache, and neck pain all showed independent relationships with higher depressive symptom scores. In practical terms, the PHQ-9 appears to capture a phenotype in which affective symptoms and bodily symptoms overlap. A patient scoring higher on the questionnaire may be signaling not only depression risk, but also a heavier burden of pain, fatigue, and physiologic stress.
Why Depression Screening Cannot Stay in a Mental Health Silo
This study pushes depression screening into a broader clinical frame. The PHQ-9 is widely used because it is brief, easy to administer, and validated for identifying depressive symptom burden. Yet its relationship with nonpsychiatric illness is often treated as a side issue. These data argue against that separation. Depression should be considered a comorbidity in common disease, not an isolated diagnostic category detached from the rest of the chart.
That view is especially important in patients with chronic respiratory symptoms, musculoskeletal pain, reflux, and metabolic risk. These conditions can erode quality of life, interrupt sleep, lower activity, and feed fatigue and mood change. Once that cycle starts, the PHQ-9 may reflect both the patient’s mental state and the collateral effects of ongoing disease. For clinicians, a rising score should prompt more than a yes-or-no question about sadness. It should trigger attention to symptom clusters, untreated medical problems, and the possibility that depression is amplifying disease burden or being amplified by it.
What the Cross-Sectional Design Can and Cannot Show
The analysis was cross-sectional, so it cannot establish directionality. Higher PHQ-9 scores may accompany more comorbidity, but the design cannot tell whether depressive symptoms worsen physical illness, whether chronic illness drives depressive symptoms, or whether both arise from shared biological and social drivers. The study also measured participants at intake, which captures an important snapshot but not the trajectory of symptoms over time.
Even with those limits, the findings are clinically useful because they identify a recurring bedside pattern. Patients with higher PHQ-9 scores were not simply reporting more sadness. They were also more likely to carry a denser burden of chronic disease, altered physical status, and persistent somatic symptoms. That combination should change how screening results are interpreted in primary care, internal medicine, and specialty clinics alike.
A Practical Interpretation for Everyday Care
The study suggests that a higher PHQ-9 score can function as a marker of whole-person vulnerability. In a patient with back pain, reflux, asthma, headaches, fatigue, memory complaints, or shortness of breath, a positive screen should not be treated as an endpoint. It should be the start of a broader clinical review that asks what medical conditions are active, which symptoms remain undertreated, and whether depression is worsening adherence, recovery, or functional status.
The data also support a more population-oriented view. Because the cohort was selected to represent major demographic groups in the USA, the associations are not confined to a narrow specialty clinic sample. They speak to the overlap between mental health symptoms and general medical burden in routine practice, where the same patient may need cardiovascular risk assessment, pain management, asthma control, and depression evaluation in the same visit.
The study leaves one central limitation in place: PHQ-9 scores identify correlated burdens, but they do not explain the mechanism driving them. The relationship between mood symptoms, pain, inflammation, cardiometabolic risk, and functional decline still needs longitudinal study before clinicians can say how best to interrupt the cycle.